Stefania Beato

Stefania Beato is the Head of pCMC, Therapeutic Modalities pRED at Roche, where they specialize in oral drug absorption, preclinical formulation, and solubility and dissolution science. Prior to their current role, Stefania served as Team Head for PHAD oral early phase at Novartis from 2018 to 2021 and worked as a principal scientist at GlaxoSmithKline from 2001 to 2010. Stefania holds degrees in Chemistry and Pharmaceutical Technologies from the University of Camerino and Université du Droit et de la Santé (Lille II).